BTG gains dielectrophoresis, dialysis technology rights
This article was originally published in Clinica
UK technology transfer company BTG's health, medical and biotechnologies division has gained commercialisation rights to two technologies - one has market potential in the $25 billion dialysis market, while the other is a microelectronics and life sciences patent portfolio with diagnostic possibilities.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.